MicroRNAs regulate the epithelial to mesenchymal transition (EMT) in cancer progression

Yang Hu, Hua Tang1

  • 1No. 22 Qi-Xiang-Tai Road, Tianjin 300070 China. htang2002@yahoo.com.

Insights

MicroRNAs (miRNAs) regulate gene expression and are crucial in cancer progression. This review details how miRNAs influence the epithelial-mesenchymal transition (EMT), impacting tumor invasion and metastasis for better cancer prognostication and therapy.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression post-transcriptionally.
  • miRNAs play critical roles in cellular processes, including cancer development and spread.
  • The epithelial-mesenchymal transition (EMT) is a key process in tumor invasion and metastasis.

Purpose of the Study:

  • To review the role of miRNAs in regulating the epithelial-mesenchymal transition (EMT).
  • To highlight the importance of miRNA-mediated EMT in cancer progression.
  • To identify potential therapeutic targets and improve cancer prognostication.

Main Methods:

  • Literature review of studies on miRNAs, EMT, and cancer.
  • Analysis of signaling pathways and molecular events influenced by miRNAs during EMT.
  • Synthesis of current knowledge on miRNA involvement in cancer metastasis.

Main Results:

  • miRNAs significantly influence the molecular pathways defining EMT.
  • Specific miRNAs have been identified that promote or inhibit EMT.
  • Dysregulation of miRNAs is linked to increased tumor invasion and metastasis.

Conclusions:

  • miRNAs are critical regulators of EMT and cancer progression.
  • Understanding miRNA-EMT interactions offers new avenues for cancer therapy.
  • miRNA profiling may enhance cancer prognostication and treatment strategies.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.6K
MicroRNAs01:22

MicroRNAs

9.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K